Tech Company Financing Transactions
Atavistik Bio Funding Round
Atavistik Bio, operating out of Cambridge, secured $40 million from Lux Capital, Nextech Invest and The Column Group.
Transaction Overview
Company Name
Announced On
12/19/2023
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds will support lead precision oncology program into the clinic and advance earlier stage pipeline
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Atavistik Bio's high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature's own mechanisms of allosteric control.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Josey
Founder
Ralph DeBerardinis
Founder
Jared Rutter
President
Marion Dorsch
Browse more venture capital transactions:
Prev: 12/19/2023: ImpriMed venture capital transaction
Next: 12/19/2023: Unnatural Products venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs